Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

RUBIUS THERAPEUTICS, INC.

(RUBY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société RUBIUS THERAPEUTICS, INC.
10/04RUBIUS THERAPEUTICS : Announces Preclinical Data for RTX-224, a Broad Immune Costimulatory..
AQ
10/01RUBIUS THERAPEUTICS : Announces Preclinical Data for RTX-224, a Broad Immune Costimulatory..
GL
09/01Rubius Therapeutics to Participate in the Morgan Stanley 19th Annual Global Healthcare ..
GL
08/30Rubius Therapeutics Appoints Jim Jogerst as Chief Business Officer
GL
08/20RUBIUS THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Resu..
AQ
08/10RUBIUS THERAPEUTICS : Reports Second Quarter 2021 Financial Results and Provides Business ..
AQ
08/09RUBIUS THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Resu..
AQ
08/09RUBIUS THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial State..
AQ
08/09RUBIUS THERAPEUTICS : Reports Second Quarter 2021 Financial Results and Provides Business ..
AQ
07/29RUBIUS THERAPEUTICS : Appoints Dannielle Appelhans as Chief Operating Officer (Form 8-K)
PU
07/29RUBIUS THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statement..
AQ
07/29RUBIUS THERAPEUTICS : Appoints Dannielle Appelhans as Chief Operating Officer
AQ
07/22RUBIUS THERAPEUTICS : to Announce Second Quarter 2021 Financial Results
AQ
07/15RUBIUS THERAPEUTICS : Announces Publication of RTX-240 Preclinical Data in Cancer Immunolo..
AQ
06/28RUBIUS THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Creation of a Dire..
AQ
06/24RUBIUS THERAPEUTICS : Announces First Patient Dosed with RTX-240 in Combination with KEYTR..
AQ
06/23Rubius Therapeutics Announces First Patient Dosed with RTX-240 in Combination with KEYT..
GL
05/20Rubius Therapeutics to Participate in Jefferies Virtual Healthcare Conference
GL
05/19Rubius Therapeutics to Present Trials in Progress Poster on the Phase 1 Clinical Trial ..
GL
05/13RUBIUS THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/12RUBIUS THERAPEUTICS : Announces Publication of RTX-321 Preclinical Data in Nature Communic..
AQ
05/12RUBIUS THERAPEUTICS : Continued Progress in Advancing Clinical Programs with Further Enrol..
PU
05/10RUBIUS THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Resu..
AQ
05/10RUBIUS THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial State..
AQ
05/10RUBIUS THERAPEUTICS : Reports First Quarter 2021 Financial Results and Provides Business U..
AQ
04/26Rubius Therapeutics to Announce First Quarter 2021 Financial Results
GL
04/12Rubius Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of RTX-321 ..
GL
04/09Rubius Therapeutics Presents Initial Clinical Results from the Ongoing Phase 1/2 Clinic..
GL
03/18RUBIUS THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Financial Statemen..
AQ
03/16Rubius Therapeutics Prices Upsized Public Offering of Common Stock
GL
03/16RUBIUS THERAPEUTICS : Prices Upsized Public Offering of Common Stock
AQ
03/15Rubius Therapeutics Announces Proposed Public Offering of Common Stock
GL
03/15RUBIUS THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
03/15Rubius Therapeutics Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-2..
GL
03/12Rubius Therapeutics Announces Webcast to Review Initial Clinical Data from Ongoing Phas..
GL
03/10Rubius Therapeutics to Present Initial Clinical Results from the Ongoing Phase 1/2 Clin..
GL
02/23RUBIUS THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Resu..
AQ
02/23RUBIUS THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial State..
AQ
02/23RUBIUS THERAPEUTICS : Reports Fourth Quarter and Full Year 2020 Financial Results and Prov..
AQ
02/18RUBIUS THERAPEUTICS : to Participate in the 10th Annual SVB Leerink Global Healthcare Conf..
AQ
02/09RUBIUS THERAPEUTICS : to Announce Fourth Quarter and Full Year 2020 Financial Results
AQ
02/04RUBIUS THERAPEUTICS : to Participate in Guggenheim Healthcare Talks 2021 Oncology Days
AQ
02/03Rubius Therapeutics to Participate in Guggenheim Healthcare Talks | 2021 Oncology Days
GL
01/12RUBIUS THERAPEUTICS : Provides Operational Update and Outlines 2021 Objectives at the 39th..
AQ
01/11RUBIUS THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
01/11RUBIUS THERAPEUTICS : Provides Operational Update and Outlines 2021 Objectives at the 39th..
AQ
01/05RUBIUS THERAPEUTICS : to Present at the Virtual 39th Annual J.P. Morgan Healthcare Confere..
AQ
01/04Rubius Therapeutics to Present at the Virtual 39th Annual J.P. Morgan Healthcare Confer..
GL
2020Rubius Therapeutics to Participate in Evercore ISI 3rd Annual HealthCONx Conference
GL
2020RUBIUS THERAPEUTICS : Named to the List of Top Places to Work in Massachusetts by the Bost..
AQ
2020RUBIUS THERAPEUTICS : to Participate in Jefferies Virtual London Healthcare Conference
AQ
2020Rubius Therapeutics to Participate in Jefferies Virtual London Healthcare Conference
GL
2020RUBIUS THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Resu..
AQ
2020RUBIUS THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial State..
AQ
2020RUBIUS THERAPEUTICS : Reports Third Quarter 2020 Financial Results and Strong Execution Ac..
AQ
2020Rubius Therapeutics Reports Third Quarter 2020 Financial Results and Strong Execution A..
GL
2020RUBIUS THERAPEUTICS : Presents Preclinical Data for Lead Red Cell Therapeutic™ Clini..
AQ
2020Rubius Therapeutics Presents Preclinical Data for Lead Red Cell Therapeutic™ Clin..
GL
2020RUBIUS THERAPEUTICS : Announces Dosing of First Patient with Relapsed/Refractory Acute Mye..
AQ
2020Rubius Therapeutics Announces Dosing of First Patient with Relapsed/Refractory Acute My..
GL
2020RUBIUS THERAPEUTICS : to Announce Third Quarter 2020 Financial Results
AQ
2020Rubius Therapeutics to Announce Third Quarter 2020 Financial Results
GL
2020RUBIUS THERAPEUTICS : Presents Preclinical Data for RTX-321, a Red Cell Therapeutic Oncolo..
AQ
2020RUBIUS THERAPEUTICS : Presents Preclinical Data for RTX-321, a Red Cell Therapeutic™..
AQ
2020Rubius Therapeutics Presents Preclinical Data for RTX-321, a Red Cell Therapeutic&trade..
GL
2020RUBIUS THERAPEUTICS : Announces Preclinical Data Supporting its Lead Clinical Oncology Pro..
AQ
2020RUBIUS THERAPEUTICS : Announces Preclinical Data Supporting its Lead Clinical Oncology Pro..
AQ
2020Rubius Therapeutics Announces Preclinical Data Supporting its Lead Clinical Oncology Pr..
GL
2020RUBIUS THERAPEUTICS : to Participate in 7th Annual Jefferies Cell Therapy Summit
AQ
2020RUBIUS THERAPEUTICS : to Participate in 7th Annual Jefferies Cell Therapy Summit
AQ
2020Rubius Therapeutics to Participate in 7th Annual Jefferies Cell Therapy Summit
GL
2020RUBIUS THERAPEUTICS : Appoints Jose Carmona as Chief Financial Officer
AQ
2020RUBIUS THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statement..
AQ
2020RUBIUS THERAPEUTICS : Appoints Jose Carmona as Chief Financial Officer
AQ
2020Rubius Therapeutics Appoints Jose Carmona as Chief Financial Officer
GL
1  2Next
Upcoming event on RUBIUS THERAPEUTICS, INC.